Meeting
2014 ASCO Annual Meeting
Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial.
Authors
Jean Tredaniel
Groupe Hospitalier Paris Saint-Joseph, Paris, France
Jean Tredaniel , Fabrice Barlesi , Cecile Le Pechoux , Delphine Lerouge , Eric Pichon , Sylvestre Le Moulec , Lionel Moreau , Sylvie Friard , Virginie Westeel , Lidia Petit , Olivier Carre , Francois Guichard , Olivier Raffy , Julie Villa , Alain Prevost , Marie Paule Lebitasy , Franck Morin , Gerard Zalcman , Francoise Mornex
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01102231
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7511^)
DOI
10.1200/jco.2014.32.15_suppl.7511
Abstract #
7511^
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non–small-cell lung cancer (NSCLC): KEYNOTE-799.
First Author: Salma K. Jabbour
Poster
2024 ASCO Breakthrough
Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.
First Author: Minji Uh
Poster
2019 ASCO Annual Meeting
Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.
First Author: Felix Keil
Poster
2017 ASCO Annual Meeting
A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation.
First Author: Ligang Xing